Last updated: May 30, 2026
Executive summary: The supplier base for neomycin and polymyxin B sulfates + hydrocortisone is split across (1) API and intermediate manufacturers for each active ingredient and (2) finished-dose sterile manufacturing for ophthalmic or otic suspensions/ointments. Product availability and sourcing depend on whether the target is ophthalmic (often sterile suspension or ointment), otic (sterile suspension), or combination packaging for branded/generic labeling. The supplier set also varies by dosage form and strength, with limited players able to supply all three actives through one integrated procurement channel.
Which companies supply neomycin, polymyxin B, and hydrocortisone APIs for combination products?
Featured snippet answer: API supply is generally fragmented: neomycin sulfate is sourced from multiple antibiotic-manufacturing sites; polymyxin B sulfate comes from a smaller set of suppliers due to fermentation and purification complexity; hydrocortisone is supplied by broader steroid API makers. Finished-dose supply then consolidates to a smaller group of sterile formulation and fill-finish manufacturers.
Neomycin sulfate API supplier profile (what to look for)
Neomycin sulfate is an aminoglycoside antibiotic produced via fermentation and purification (or via semi-synthetic downstream processing depending on grade). Buyers typically screen suppliers on:
- Microbiology release controls and impurity profiles
- Potency consistency across commercial lots
- Availability of USP/EP-compliant material grades
Polymyxin B sulfate API supplier profile (smaller supplier set)
Polymyxin B sulfate is produced by fermentation, then purification, with tight control of:
- Peptide profile (mixture nature and lot-to-lot variability)
- Related impurities
- Potency and dissolution suitability for suspension/ointment formulations
Hydrocortisone API supplier profile (broader base)
Hydrocortisone is manufactured via established steroid chemical routes. Buyers typically validate:
- Steroid particle size / polymorph profile where relevant
- Consistent impurity spectrum and stability data
What finished-dose manufacturers supply neomycin/polymyxin B/hydrocortisone ophthalmic or otic products?
Featured snippet answer: Finished-dose supply is dominated by contract manufacturers that can handle sterile suspension or ointment production plus packaging for the labeled strengths and container/closure systems.
Common dosage forms buyers procure
- Ophthalmic suspension (sterile)
- Otic suspension (sterile)
- Ophthalmic ointment / otic ointment (semisolid)
Why dosage form drives supplier eligibility
- Sterile suspension requires validated aseptic processing, filtration strategy, and microbial limits.
- Ointment uses different blending and fill profiles and often different containment and cleaning validation.
How do the supplier options differ by dosage form (ophthalmic suspension vs otic suspension vs ointment)?
Featured snippet answer: The tightest bottlenecks are usually sterile suspension fill-finish capacity and validated container compatibility. Ointment manufacturing is comparatively less constrained but still requires GMP quality systems and stability support.
Sterile suspension: key manufacturing constraints
- Aseptic processing validation
- Filter compatibility with antibiotic systems
- End-to-end particulate control
- Container closure compatibility with suspensions
Ointment: key manufacturing constraints
- Mixing and homogeneity controls
- Antibiotic stability in semisolid matrices
- Tube or vial fill validation
- Overfill and residuals testing
What raw-material procurement strategy reduces risk for triple-active combinations?
Featured snippet answer: Companies usually reduce risk by dual-sourcing at the API level and contracting fill-finish with a site that can qualify multiple API lots and manage lot segregation.
Typical procurement architectures
- Single contract manufacturer buys and manages all APIs, then produces finished product under QMS-controlled sourcing.
- Buyer-supplied APIs into a contract facility (requires tighter incoming qualification).
- Hybrid sourcing where one active is buyer-supplied and the other two are managed by the CDMO.
What are the key regulatory and quality gates suppliers must meet (GMP, data package, release testing)?
Featured snippet answer: Suppliers must meet GMP and provide a qualification package that supports:
- API specification and CoA formats
- Stability program summaries or bridging data
- Impurity controls, including antibiotic-related impurities and steroid impurities
- Microbiology and sterility assurance where relevant for the finished dosage
Documentation that procurement teams typically require
- GMP certificates and site audit summaries
- Drug Master File (DMF) cross-reference if used
- Analytical method descriptions sufficient for comparability
- Change control history for each active
Which risks exist when sourcing antibiotics like neomycin and polymyxin B for combination sterile products?
Featured snippet answer: Risk clusters around lot variability, potency drift, and supply continuity for fermentation-derived antibiotics, with downstream risk in formulation performance (suspension behavior, sedimentation rate, and uniformity).
Practical risk controls in sourcing
- Dual or multi-source API procurement for antibiotics
- Incoming testing plans aligned with formulation needs
- Qualified alternate suppliers for each active
- Packaging and container closure compatibility verification for each API lot
What does a supplier qualification checklist look like for this triple-active combination?
Featured snippet answer: Qualification focuses on analytical comparability, stability, and GMP compliance across APIs and the sterile process.
API qualification checklist (buyer perspective)
- CoA review for assay, impurities, and microbiological limits
- Stability data review or bridging protocol
- Traceability and batch genealogy
- Method capability check for potency assay
Finished-dose qualification checklist (CDMO perspective)
- Aseptic process validation and media fills
- Container closure system validation
- Microbial limits and environmental monitoring
- Uniformity testing strategy for suspension
Which contract manufacturing categories matter most: API vs sterile fill-finish vs packaging?
Featured snippet answer: For this combination, sterile fill-finish and packaging are the most restrictive categories for direct supply. API sourcing can be more distributed, but antibiotics often determine long-lead procurement.
Three procurement workstreams
- API procurement (neomycin sulfate, polymyxin B sulfate, hydrocortisone)
- Drug product manufacturing (aseptic suspension/ointment)
- Packaging and labeling integration (tubes/vials, cartons, inserts)
Supplier mapping table for procurement planning (how to structure vendor discovery)
| Supply tier |
What to source |
Qualification focus |
Main bottleneck |
| API suppliers |
Neomycin sulfate |
Potency, impurities, microbiology |
Continuity and lot consistency |
| API suppliers |
Polymyxin B sulfate |
Peptide profile, potency, impurities |
Smaller supplier pool |
| API suppliers |
Hydrocortisone |
Impurities, polymorph/particle effects |
Standard chemical supply |
| CDMOs |
Sterile suspension/ointment |
Aseptic controls, uniformity, stability |
Sterile capacity and fill-finish |
| Packers |
Tubes/vials/cartons |
Container closure compatibility |
Packaging lines and spec adherence |
Commercial sourcing: how do branded vs generic products affect the supplier list?
Featured snippet answer: Generic and rebranded products often broaden supplier options via multiple API grades and alternate CDMOs, but sterile performance and stability testing still constrain the final set of qualified manufacturers.
Typical impacts
- Generic programs may accept different but qualified API grades (subject to comparability).
- Branded programs often lock into fewer qualified sites and suppliers, increasing continuity risk if supply disruptions occur.
Key Takeaways
- Supplier coverage for neomycin and polymyxin B sulfates plus hydrocortisone is typically fragmented at the API level and consolidated at the sterile drug product level.
- The most constrained procurement category is usually sterile suspension fill-finish and validated container closure systems.
- The highest supply-chain risk tends to sit with fermentation-derived polymyxin B sulfate and lot-to-lot potency consistency for antibiotics.
- A defensible sourcing strategy uses dual-sourcing at API level and qualified alternate lots with a CDMO capable of assimilating multiple upstream materials.
FAQs
1) Can one supplier provide neomycin, polymyxin B, and hydrocortisone APIs under a single procurement umbrella?
Some suppliers offer integrated API supply, but most programs still validate qualification across multiple upstream sites due to fermentation antibiotic constraints.
2) What supply chain stage is most likely to delay launches for these combinations?
Sterile drug product manufacturing timelines and validated fill-finish slots typically drive schedule risk more than hydrocortisone chemical supply.
3) Do suppliers differ materially by ophthalmic versus otic packaging formats?
Yes. Even if the actives and strengths match, container closure compatibility, sterility assurance testing, and local labeling requirements can change the qualified supplier set.
4) How do buyers mitigate polymyxin B supply disruptions?
They qualify alternate API sources, increase safety stock for long lead antibiotics, and align incoming QC acceptance criteria with formulation needs.
5) What matters most in API lot acceptance for antibiotic suspensions?
Potency, impurity spectrum, and microbiological limits, paired with suspension performance uniformity and stability.
References (APA)
- FDA. (n.d.). Drug shortage database. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- EMA. (n.d.). EU GMP guidelines. European Medicines Agency. https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/good-manufacturing-practice-gmp
